Skip to main content

Change location

You are currently on the Czech Republic (Český) website

My country is not on the list

Global

  • Bracco.com (English)

Asia

  • China (中文)
  • Japan (日本語)
  • South Korea (한국어)

Americas

  • Brazil (Português)
  • Canada (English)
  • Mexico (Español)
  • Canada (Français)
  • USA (English)

Europe

  • Austria (English)
  • Belgium (English)
  • Czech Republic (English)
  • Denmark (English)
  • Finland (English)
  • France (Français)
  • Germany (Deutsch)
  • Iceland (English)
  • Italy (Italiano)
  • Luxembourg (English)
  • Norway (English)
  • Poland (English)
  • Slovakia (English)
  • Sweden (English)
  • Switzerland (English)
  • The Netherlands (English)
  • UK (English)
  • Czech Republic (Český)
  • Careers
  • Media and News
  • Get in touch
    • Czech Republic (English)
    • We are Bracco
    • Our businesses
    • Purpose and values
    • Our history
    • Our Foundation
    • Responsibility and Ethical conduct
    • Product overview
      • X-ray/CT
      • Contrast agents

      • Medical devices

        • CT Exprès 3D
        • Empower CTA+
      • MRI
      • Contrast agents

        • MultiHance
        • ProHance
        • Vueway
      • Medical Devices

        • Empower MR
      • CEUS
      • Contrast agents

        • Sonovue
      • Software

        • VueBox
    • Molecular imaging
    • Cardiovascular
    • Digital health
    • Oncology
    • Cardiology
    • Digital future
    • R&D
    • The Bracco sites
    • Scientific heritage and patents
    • Education
    • Next-Gen Projects
    • Bracco Global Academy
    • Our Partnerships
    • Events
    • Our sustainability pillars
    • Governance and transparency
    • Sustainability report
  • Our Stories
154 results found
Page
Scientific Information Inquiry Fill in this form to receive information about medical and clinical aspects of a product.
No image available
Product
The European Commission granted Marketing Authorisation for VUEWAY® (gadopiclenol ) for its use in pediatric patients under 2 years Bracco Imaging S.p.A., a global leader in diagnostic imaging, announces announces that on January 23, 2026, the European Commission (EC) granted the Marketing Authorisation for gadopiclenol in the European Union (EU) for pediatric patients below 2 years of age. 
The CHMP adopted a positive opinion for gadopiclenol use in pediatric patients under 2
Article
The European Commission granted Marketing Authorisation for gadopiclenol for its use in pediatric patients under 2 years Bracco Imaging S.p.A., a global leader in diagnostic imaging, announces announces that on January 23, 2026, the European Commission (EC) granted the Marketing Authorisation for gadopiclenol in the European Union (EU) for pediatric patients below 2 years of age. 
The CHMP adopted a positive opinion for gadopiclenol use in pediatric patients under 2
Article
Bracco Announces EU Launch of AiMIFY and Expands AI Portfolio At the 2026 European Congress of Radiology (ECR), Bracco Imaging S.p.A. today announced two major milestones in its AI & Digital Health strategy: the commercial launch in the European Union of AiMIFY® and a new strategic partnership with Avicenna.AI.
Bracco Announces EU Launch of AiMIFY and Expands AI Portfolio

The Bracco Group is an international group of highly specialized companies.
We are an active part of the healthcare sector, and a global leader in diagnostic imaging.

  • We are Bracco
  • Our Portfolio
  • Innovation
  • Knowledge
  • Sustainability
  • Our Stories
  • Farmakovigilance
  • VPOIS
  • Data Protection

Connect with us

Bracco Imaging Czech s.r.o.
Novodvorská 994 / 138
142 21 Praha 4
Czech Republic
VAT No CZ 24119393
+420 239 044 300

  • Terms of Use
  • Privacy Policy
  • Cookie Policy
  • Imprint
  • for Bracco VPN users

Bracco Copyright © 2026 | Registered office: Via E. Folli, 50, 20134 Milano, Italy | Share Capital € 104.000.000 f.p. | VAT Milan Comp. Reg. n. 00825120157 | Milan REA n. 348182